maraviroc

(redirected from Selzentry)
Also found in: Medical.
Related to Selzentry: Celsentri
Translations

maraviroc

n maraviroc m
References in periodicals archive ?
Market Access Impact: HIV explores how cost concerns and other barriers affect market share for 8 major HIV treatments: Evotaz, Intelence, Isentress, Selzentry, Stribild, Triumeq, Truvada, and Viread.
Maraviroc tablets, 150 mg, Hetero Labs Selzentry tablets
Slightly more than half (54%) were taking a protease inhibitor, while 6% were taking the integrase inhibitor Isentress (raltegravir), 3% were taking the CCR5 inhibitor Selzentry (maraviroc), and 2% were taking a nonnucleoside.
Pfizer's Chantix and Selzentry has lead the way resulting in approval without a pre-approval inspection (PM) for one molecule and a PAI with no observations related to the QbD submission for the other.
Moore s team tested Pfizer s new drug maraviroc, sold under the brand name Selzentry.
They start with 11 current products, including GSK's Combivir and Pfizer's Selzentry with six more in development.
Pfizer's maraviroc (the imaginatively named Selzentry in the USA; Celsentri elsewhere, licensed in 2007, and awaiting MCC registration in 2009) has been the first out of the starting blocks and has been approved in developed countries for treatment-experienced patients.
Increased sales of Trofile due to its clinically proven high level of sensitivity for selecting appropriate patients for CCR5 therapy and an increasingly positive profile for Selzentry, Pfizer's CCR5 antagonist, as a treatment option for a broad group of treatment-experienced HIV patients.
s (New York) Selzentry is being studied as a topical cream to prevent transmission.
Recommended Dosage: Dosage is 150 mg, 300 mg, or 600 mg twice daily, depending on concomitant antiretroviral drugs because of the effects of CYP3A inhibitors and CYP3A inducers on blood levels of Selzentry.
Because the study period ended in 2005, these findings do not reflect the impact of several newer drugs that work well after one or more antiretroviral combination failures: Prezista (darunavir), Isentress (raltegravir), Selzentry (maraviroc), and Intelence (etravirine).
Entry inhibitor anti-retroviral drugs, such as Pfizer's Selzentry therapy, which is the first in its class to be FDA approved, block the CCR5 co-receptor to inhibit disease progression.